

European Commission Initiative on Breast Cancer

Annual Declaration of Interests (ADoI)

Name:

[Please copy rows as needed for subsequent or parallel activities of the same nature]

[If it is not clear to you under which category of the form to declare an interest, you can declare it under "Other"].

Nature of activities	Period	Entity	Subject matter
1. Ownership or financial investments, including shares	NONE	NONE	NONE
2. Membership of a managing body or equivalent structure	NONE	NONE	NONE
3. Membership of another scientific advisory body	Since more than 5 years up to date	-European association for Palliative Care Research Network -Milan National Cancer Institute -Non profit organization and NGO	Promote palliative care research; Organisation of EAPC research conference Function of expert: Advisor Link to website of body: www.eapcnet.eu Responsible of cancer pain guidelines working group for EAPC-RN and PRC (see below)
	Since more than 5 years up to date	European Palliative Care Research Centre (PRC) Norwegian University for Science and Technology Trondheim	Promote clinical trials in palliative care Function: clinical investigator, advisor www.ntnu.edu/prc
	Since more than 5 years up to 31.12.2016	Scientific Committee of the Floriani Foundation, Milan, Non profit public foundation	Promote palliative care and fund palliative care activities including research www.fondazionefloriani.eu

Nature of activities	Period	Entity	Subject matter
4. Employment	09/07/2006 up to date	- Fondazione IRCCS Istituto Nazionale dei Tumori di Milano -Type: Public Hospital and National Health Care System Cancer Research and referral institution	Director of the clinical and scientific activities of the Palliative Care, Pain Therapy and Rehabilitation department
	09/2010 up to date	- Norwegian University of Science and Technology (NTNU) Trondheim Norway	Part-time associate professor of Palliative Medicine
5. Consultancy/Advisory	1-2/11/2013	- Gruenthal GmbH ; Aachen Germany -Type: Pharmaceutical Company 2000e	Advisor for clinical trials on new opioid drugs
	8/07/2013	Pfizer; New York USA Pharmaceutical Company 1740e	Advisor for the use of Tanezumab in cancer pain
	20/09/2013	Almiral; Madrid Spain Pharmaceutical Company 2000e	Advisor for the use of Sativex in cancer pain
	27/09/2014	Helsin Healthcare; Lugano Switzerland Pharmaceutical Company 1500e	Advisor for anorexia syndrome
	10-12/10/2014	Molteni & C Soc Esercizio Spa; Scandicci FI Pharmaceutical Company 1000e	Advisor in organising professional education and scientific meetings on cancer pain

Nature of activities	Period	Entity	Subject matter
	03/2014	- Gruenenthal GmbH ; Aachen Germany -Type: Pharmaceutical Company 1000e	Preparation of scientific material for cancer pain education
	12/2014	Pfizer; New York USA Pharmaceutical Company 4000e	Advisory board meetings to develop clinical trials on cancer pain
	13-14/11/2015	Italfarmaco ; Cinisello Balsamo (MI) Pharmaceutical Company 800e	Speaker at educational course
	09/2016	Sandoz International GmbH; Barleben, Germany Pharmaceutical Company 1000e	Editor for educational newsletter
	11/2016	Institute de Recherche “Pierre Fabre” ; Boulogne (France) 2400e	Advisory board meetings to develop clinical trials on cancer pain
6. Influence on definition of research priorities	NONE	NONE	NONE
7. Research grants and other funding	01/2015-12/2017	- AIRC (Italian Association for Cancer Research) -Type: Private ONLUS org. - 276.000e to Institution	Principal investigator of the MOLO study on genetic and clinical variability of the response of cancer pain to opioid pharmacotherapy
	11/2014-11/2017	National finalized research fund of the Italian Ministry of Health 77.400e to Institution	Application of early palliative care in advances pancreas and gastric cancer – workpackage leader

Nature of activities	Period	Entity	Subject matter
	09/2013-09/2015	Molteni & C Soc Esercizio Spa; 7000e institutional funding	IOPS study II on breakthrough cancer pain
	In the last 5 years	The following companies: Prostrakan, Gruenenthal GmbH, Amgen gave unrestricted grants to my Institution for a total of 40.000e	Funds were employed in independent research activities on cancer pain and palliative care
	Since 2017 up to date	Ipsen Total amount will depend on the n. of patients enrolled at the end of the study period	Pharmacological clinical trial on the effect of lanreotide in the management of malignant bowel obstruction
8. Principal investigator or investigator	SEE ABOVE	SEE ABOVE	SEE ABOVE
9. Intellectual property rights (IPR)	NONE RELEVANT	NONE RELEVANT	NONE RELEVANT
10. Other membership or affiliation	NONE RELEVANT	NONE RELEVANT	NONE RELEVANT
11. Interests of others	NONE	NONE	NONE
12. Other	NONE	NONE	NONE

I also declare on my honour that the information disclosed in this form is true and complete to the best of my knowledge. Should there be any change to the above information, I will promptly notify the responsible service of the Commission and complete a new DoI form including the changes.

Done at: _____ Date: 26.1.2018

Signature: 